Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

USA - NASDAQ:MDGL - US5588681057 - Common Stock

421.5 USD
-2.37 (-0.56%)
Last: 10/24/2025, 8:00:01 PM
421.5 USD
0 (0%)
After Hours: 10/24/2025, 8:00:01 PM
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MDGL has reported negative net income.
MDGL had a negative operating cash flow in the past year.
In the past 5 years MDGL always reported negative net income.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

MDGL's Return On Assets of -27.76% is fine compared to the rest of the industry. MDGL outperforms 70.22% of its industry peers.
Looking at the Return On Equity, with a value of -40.50%, MDGL is in the better half of the industry, outperforming 71.54% of the companies in the same industry.
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

MDGL's Gross Margin of 96.28% is amongst the best of the industry. MDGL outperforms 95.51% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDGL has more shares outstanding
Compared to 5 years ago, MDGL has more shares outstanding
MDGL has a better debt/assets ratio than last year.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

MDGL has an Altman-Z score of 15.56. This indicates that MDGL is financially healthy and has little risk of bankruptcy at the moment.
MDGL's Altman-Z score of 15.56 is amongst the best of the industry. MDGL outperforms 88.39% of its industry peers.
MDGL has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
MDGL has a Debt to Equity ratio of 0.17. This is in the lower half of the industry: MDGL underperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 15.56
ROIC/WACCN/A
WACC9.34%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 5.11 indicates that MDGL has no problem at all paying its short term obligations.
With a Current ratio value of 5.11, MDGL perfoms like the industry average, outperforming 55.99% of the companies in the same industry.
MDGL has a Quick Ratio of 4.78. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDGL (4.78) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 4.78
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.61% over the past year.
The Revenue has grown by 3421.98% in the past year. This is a very strong growth!
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%

3.2 Future

Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 37.73% on average per year.
Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 85.13% on average per year.
EPS Next Y53.71%
EPS Next 2Y46.78%
EPS Next 3Y43.55%
EPS Next 5Y37.73%
Revenue Next Year401.7%
Revenue Next 2Y184.91%
Revenue Next 3Y129.27%
Revenue Next 5Y85.13%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 123.41, which means the current valuation is very expensive for MDGL.
Based on the Price/Forward Earnings ratio, MDGL is valued cheaper than 86.89% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MDGL to the average of the S&P500 Index (22.92), we can say MDGL is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 123.41
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MDGL's earnings are expected to grow with 43.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.78%
EPS Next 3Y43.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (10/24/2025, 8:00:01 PM)

After market: 421.5 0 (0%)

421.5

-2.37 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners98.35%
Inst Owner Change0.04%
Ins Owners0.99%
Ins Owner Change-0.42%
Market Cap9.40B
Revenue(TTM)515.55M
Net Income(TTM)-281899000
Analysts81.82
Price Target488.72 (15.95%)
Short Float %18.09%
Short Ratio11.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.12%
Min EPS beat(2)13.46%
Max EPS beat(2)48.79%
EPS beat(4)4
Avg EPS beat(4)32.47%
Min EPS beat(4)13.46%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)13.82%
EPS beat(12)6
Avg EPS beat(12)8.91%
EPS beat(16)9
Avg EPS beat(16)7.2%
Revenue beat(2)2
Avg Revenue beat(2)23.38%
Min Revenue beat(2)18.22%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)31.95%
Min Revenue beat(4)2.78%
Max Revenue beat(4)78.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.79%
PT rev (3m)13.56%
EPS NQ rev (1m)-5.76%
EPS NQ rev (3m)35.03%
EPS NY rev (1m)0%
EPS NY rev (3m)24.41%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)34.64%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)27.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 123.41
P/S 18.22
P/FCF N/A
P/OCF N/A
P/B 13.5
P/tB 13.59
EV/EBITDA N/A
EPS(TTM)-12.85
EYN/A
EPS(NY)3.42
Fwd EY0.81%
FCF(TTM)-13.84
FCFYN/A
OCF(TTM)-13.79
OCFYN/A
SpS23.13
BVpS31.22
TBVpS31.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.28%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.74%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.11
Quick Ratio 4.78
Altman-Z 15.56
F-Score3
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
EPS Next Y53.71%
EPS Next 2Y46.78%
EPS Next 3Y43.55%
EPS Next 5Y37.73%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%
Revenue Next Year401.7%
Revenue Next 2Y184.91%
Revenue Next 3Y129.27%
Revenue Next 5Y85.13%
EBIT growth 1Y41.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.64%
EBIT Next 3Y44.71%
EBIT Next 5YN/A
FCF growth 1Y-11.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.99%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


What is the valuation status of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a valuation rating of 2 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


Can you provide the profitability details for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for MDGL stock?

The Earnings per Share (EPS) of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 53.71% in the next year.